APR Applied Pharma Research s.a. Email Format

Pharmaceutical ManufacturingTicino, Switzerland11-50 Employees

APR Applied Pharma Research s.a. is a Swiss biopharmaceutical company focused on the development and global commercialization of therapies for rare diseases and specialized metabolic conditions. It combines pharmaceutical development capabilities with proprietary drug-delivery technologies to address unmet medical needs and support disease management for patients and families. The company maintains a diversified portfolio of revenue-generating products in major markets and a robust pipeline spanning recessive metabolic disorders as well as rare dermatological and ocular diseases, with in-house sales teams in Europe and a growing network of commercial partners worldwide.

Based in Balerna in the Ticino region of Switzerland, APR is part of Relief Therapeutics. In 2023 the company entered into a long-term distribution agreement with Vector Pharma FZCO under the World Orphan Drug Alliance to introduce PKU GOLIKE Plus 3-16 in the Middle East. Also in 2023, APR announced the appointment of Dr. Guangping Gao as chair of its scientific advisory board and released stability data for RLF-100, its formulation of aviptadil acetate.

Sign up for free to view info

Company overview Employee directory